<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423706</url>
  </required_header>
  <id_info>
    <org_study_id>CART</org_study_id>
    <nct_id>NCT03423706</nct_id>
  </id_info>
  <brief_title>Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Building a new haploid transplanted model with high-dose CTX、CD19-CART,donor CD34+
      hematopoietic stem cell and Tregs,to prevent graft-versus-host disease(GVHD),reduce the
      infection,promote the rate of immune reconstruction，seperate graft versus leukemia（GVL）and
      GVHD，then to reduce the relapse rate after hematopoietic stem cell transplantation（HSCT）for
      relapsed and/or refractory B cell acute lymphoblastic leukemia（r/r-B-ALL）.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      compare the new haplo-HSCT model with the traditional haplo-HSCT in DFS、OS、RFS、CR and the
      degree of GVHD.etc.for the r/r B-ALL patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival at six months</measure>
    <time_frame>six months</time_frame>
    <description>the disease free survival of the new model haplo-HSCT will be assessed at 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>acute graft-versus-host disease</measure>
    <time_frame>three months</time_frame>
    <description>we will examine the treatment-related acute GVHD at 3 months.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>CD19-chimeric Antigen Receptor T Cells</condition>
  <condition>Relapsed and/or Refractory Acute Lymphoblastic Leukemia</condition>
  <condition>the Haploidentical Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>new model of haplo-HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use the new model of haplo-HSCT to treat the r/r B-ALL patients matching the inclusion criterion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>the new model of haplo-HSCT for r/r B-ALL</intervention_name>
    <description>take advantage of high-dose CTX、CD19-CART、donor CD34+HSC and Tregs to create a new model of haplo-HSCT for the patients in r/r B-ALL,to improve the quality of HSCT.</description>
    <arm_group_label>new model of haplo-HSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. the r/r B-ALL patients

          2. have the healthy allo-HSCT donor

          3. voluntary and signed the treatment protocol

        Exclusion Criteria:

          1. not match the inclusion criteria

          2. important organ is dysfunction, such as heart and/or renal dysfunction,liver failure

          3. Pregnancy or breast-feeding women

          4. has virus infection,such as HIV,hepatitis virus,and can not be cleared with anti-virus
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jin zhou, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>First affliliated hospital of Harbin medical university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>min li li, master</last_name>
    <phone>13796615495</phone>
    <email>llilimin@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First affiliated hospital of Harbin medical university</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>min li li, master</last_name>
      <phone>13796615495</phone>
      <email>llilimin@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

